MetaCap

Dyne Therapeutics Inc. (DYN)

NASDAQ: DYNHealth CareBiotechnology: Pharmaceutical PreparationsUSD

15.50-0.53 (-3.31%)

At close: Nov 20, 4:00 PM ET · Delayed 15 min

DYN stock chart

Technical analysis

Key statistics

All statistics
EPS (TTM)
-$3.62
52-week range
14.00 – 27.31
Day range
15.41 – 16.48
Volume / Avg
2.23M / 2.94M
Beta
—

52-week range

$14.00$27.31

DYN stock today

Shares of Dyne Therapeutics (DYN) finished lower on Nov 20 at $15.50, a drop of 3.31% or $0.53 per share, versus the S&P 500's 3.70% decline. Shares are 43.2% below their 52-week high of $27.31, set on Aug 12, 2026 and 10.7% above the 52-week low of $14.00, near the bottom of the past year's range. DYN is down 20.8% year to date, underperforming the S&P 500 (+1.2%). Over the past 12 months, the stock has lost 26.8%.

Dyne Therapeutics has posted a net loss over the last twelve months (EPS of -$3.62), so its P/E ratio is not meaningful.

Summary generated from market data by MetaCap's automated system. Methodology

About Dyne Therapeutics

Company profile

Dyne Therapeutics, Inc., a clinical-stage neuromuscular disease company, focuses on discovering and developing therapeutics for neuromuscular diseases in the United States. The company is developing a portfolio of muscle disease therapeutics, including programs in myotonic dystrophy type 1; duchenne muscular dystrophy; facioscapulohumeral dystrophy; and Pompe disease, as well as rare skeletal muscle, and cardiac and metabolic muscle diseases using its FORCE platform that delivers disease-modifying therapeutics. Dyne Therapeutics, Inc.

Industry
Biotechnology: Pharmaceutical Preparations
CEO
Mr. John G. Cox M.B.A.
Headquarters
Waltham, MA
Employees
322
IPO year
2020

Financial highlights

Full financials

Dyne Therapeutics reported a net loss of $446.2 million, compared with a loss of $317.4 million a year earlier. Diluted earnings per share came in at -$3.47.

Dyne Therapeutics annual revenue, net income and EPS
Fiscal yearFY 2025FY 2024FY 2023FY 2022FY 2021
Revenue—————
Growth—————
Net income$-446.21M$-317.42M$-235.94M$-168.10M$-149.29M
EPS (diluted)$-3.47$-3.37$-3.95$-3.23$-2.93

Analyst forecast

Forecast

Consensus (17 analysts)

strong_buy

Avg. price target

$34.33+121.48%

  • Strong buy 3
  • Buy 12
  • Hold 1
  • Sell 0
  • Strong sell 1

Target range

Low $10.00High $50.00

Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.

Earnings

Earnings history
Last reported (Sep/2026)
Nov 5, 2026
EPS actual vs est.
$-1.06 vs $-0.88
Surprise
-20.45%

DYN news

All DYN news

Dyne Therapeutics peers

Health Care sector
DYN peer companies
CompanyPrice% ChgMarket capCompare
ACADACADIA Pharmaceuticals Inc.17.11-2.73%$2.96Bvs DYN
LEGNLegend Biotech Corporation ADR15.25-5.28%$2.96Bvs DYN
TLXTelix Pharmaceuticals Limited ADR8.37-3.90%$2.84Bvs DYN
SLSSELLAS Life Sciences Group Inc.13.66-8.08%$2.78Bvs DYN
BHCBausch Health Companies Inc.8.22-3.97%$3.08Bvs DYN
XERSXeris Biopharma Holdings Inc.16.97+2.11%$3.10Bvs DYN
VKTXViking Therapeutics Inc.24.77-4.14%$3.16Bvs DYN
ABCLAbCellera Biologics Inc.9.69-7.45%$3.16Bvs DYN

Indexes, lists and sector

Dyne Therapeutics stock FAQ

What is Dyne Therapeutics's stock price today?

DYN last traded at $15.50 as of Nov 20, 4:00 PM EST, down 3.31% on the day. Prices are delayed at least 15 minutes.

Who is Dyne Therapeutics's CEO?

Mr. John G. Cox M.B.A. is the chief executive officer of Dyne Therapeutics Inc., which has about 322 employees.

What is the DYN 52-week high?

The 52-week high for DYN is $27.31 and the 52-week low is $14.00. The stock is currently 43.2% below its high.

Compare DYN